Jade Biosciences Inc [JBIO] stock prices are up 2137927% to $276100.0 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The JBIO shares have gain 42.51% over the last week, with a monthly amount glided 28.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jade Biosciences Inc [NASDAQ: JBIO] stock has seen the most recent analyst activity on June 16, 2025, when Guggenheim upgraded its rating to a Buy but kept the price target unchanged to $14 for it. Previously, Wedbush started tracking the stock with Outperform rating on May 07, 2025, and set its price target to $17. On May 05, 2025, Stifel initiated with a Buy rating and assigned a price target of $19 on the stock. TD Cowen started tracking the stock assigning a Buy rating and suggested a price target of $10 on May 02, 2025. Wells Fargo downgraded its rating to a Equal Weight and reduced its price target to $2 on June 18, 2024. TD Cowen downgraded its rating to Hold for this stock on June 18, 2024. In a note dated June 18, 2024, Evercore ISI downgraded an In-line rating on this stock and revised its target price from $27 to $2.
The stock price of Jade Biosciences Inc [JBIO] has been fluctuating between $4.57 and $13.50 over the past year. Currently, Wall Street analysts expect the stock to reach $16.5 within the next 12 months. Jade Biosciences Inc [NASDAQ: JBIO] shares were valued at $276100.0 at the most recent close of the market. An investor can expect a potential drop of -99.99% based on the average JBIO price forecast.
Analyzing the JBIO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.29, Equity is 2.01 and Total Capital is -1.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Jade Biosciences Inc [NASDAQ:JBIO]’s Current Ratio is 32.01. Further, the Quick Ratio stands at 32.01, while the Cash Ratio is 5.78.
Transactions by insiders
Recent insider trading involved Frohlich Tom, Chief Executive Officer, that happened on May 16 ’25 when 6000.0 shares were purchased. Shareholder, Atlas Venture Associates XII, completed a deal on May 06 ’25 to buy 48.0 shares. Meanwhile, Shareholder Atlas Venture Fund XII, L.P. bought 5883.0 shares on May 06 ’25.
